Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant

By Schuster Michael  

Supportive Care in Cancer, Vol. 16, Iss. 5, 2008-05 ,pp. : 477-483

Springer Publishing Company

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite

Very High-dose Chemotherapy with Autologous Peripheral Stem Cell Support in Advanced Ovarian Cancer

By Benedetti-Panici P.   Greggi S.   Scambia G.   Salerno M.G.   Baiocchi G.   Laurelli G.   Menichella G.   Pierelli L.   Foddai M.L.   Serafini R.   Bizzi B.   Mancuso S.  

European Journal of Cancer, Vol. 31, Iss. 12, 1995-11 ,pp. : 1987-1992

Elsevier

Access to resources Recommend Favorite

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

By Gluck S.   Germond C.   Lopez P.   Cano P.   Dorreen M.   Koski T.   Arnold A.   Dulude H.   Gallant G.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1008-1014

Elsevier

Access to resources Recommend Favorite

Pilot Evaluation of High-Dose Carboplatin and Paclitaxel Followed by High-Dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

By Schilder R.J.   Brady M.F.   Spriggs D.   Shea T.  

Gynecologic Oncology, Vol. 88, Iss. 1, 2003-01 ,pp. : 3-8

Academic Press

Access to resources Recommend Favorite